Adjuvant S‐1 vs gemcitabine for node‐positive perihilar cholangiocarcinoma: A propensity score‐adjusted analysis

作者
Daigoro Takahashi,Takashi Mizuno,Yukihiro Yokoyama,Tsuyoshi Igami,Junpei Yamaguchi,Shunsuke Onoe,Nobuyuki Watanabe,Osamu Maeda,Masahiko Ando,Tomoki Ebata
出处
期刊:Journal of Hepato-biliary-pancreatic Sciences [Wiley]
卷期号:28 (9): 716-726 被引量:14
标识
DOI:10.1002/jhbp.1005
摘要

BACKGROUND: The efficacy of adjuvant chemotherapy for biliary cancers remains controversial because of conflicting results from previous phase 3 studies that used different key drugs and enrolled patients with heterogeneous tumor sites and disease stages. Fluoropyrimidine seems more beneficial than gemcitabine (GEM) combination regimens in the adjuvant setting; however, data comparing the survival benefit between GEM- and fluoropyrimidine-based regimens are lacking. METHODS: Patients who underwent resection for node-positive perihilar cholangiocarcinoma were included. The patients who underwent adjuvant chemotherapy were divided into the S-1 and GEM groups according to the regimen. The recurrence-free survival (RFS) and the overall survival (OS) were compared between the groups and adjusted with propensity scores generated from 14 potentially confounding clinicopathological factors. RESULTS: In total, 186 patients (Surgery alone, n = 71; S-1, n = 60; GEM, n = 55) were included. The S-1 and GEM completion rates were 75% and 65%, respectively. Among the patients who underwent adjuvant therapy, the RFS was longer in the S-1 group patients than the GEM group patients (median, 24.4 months vs 14.9 months; P = .044) whereas the OS was not significantly different between the groups (median, 48.5 months vs 35.0 months; P = .324). After propensity score adjustment, the differences in RFS and OS between the groups were more evident (HR: 2.696, 95% CI: 1.739-4.180 P < .001; HR: 1.988, 95% CI: 1.221-3.238, P < .001, respectively). CONCLUSIONS: Compared with adjuvant GEM monotherapy, adjuvant S-1 monotherapy may improve survival in node-positive perihilar cholangiocarcinoma patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿的应助被Rocky采纳,获得10
刚刚
刚刚
1秒前
1秒前
复活发布了新的文献求助30
1秒前
细腻驳完成签到,获得积分10
2秒前
2秒前
荼蘼发布了新的文献求助10
2秒前
昏睡的半莲完成签到,获得积分10
3秒前
3秒前
3秒前
Hase发布了新的文献求助10
4秒前
社恐小柠檬完成签到,获得积分10
4秒前
4秒前
aw完成签到,获得积分20
4秒前
5秒前
5秒前
5秒前
pump完成签到,获得积分20
5秒前
风吹麦浪的应助被Eli采纳,获得10
6秒前
6秒前
烟花的应助被4645采纳,获得10
8秒前
张可欣完成签到,获得积分10
9秒前
10秒前
正直未来完成签到,获得积分10
10秒前
张智磊发布了新的文献求助10
11秒前
11秒前
狂野的山菡完成签到,获得积分10
12秒前
荼蘼发布了新的文献求助10
12秒前
13秒前
13秒前
科研通AI2S的应助被开放满天采纳,获得10
15秒前
15秒前
村民完成签到 ,获得积分10
15秒前
molihuakai的应助被活泼的枕头采纳,获得10
17秒前
xucc发布了新的文献求助10
17秒前
喵喵拳发布了新的文献求助10
17秒前
17秒前
super完成签到,获得积分10
17秒前
parad1se完成签到,获得积分10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175157
求助须知:如何正确求助?哪些是违规求助? 9566975
关于积分的说明 21789458
捐赠科研通 7769647
什么是DOI,文献DOI怎么找? 3431836
关于科研通互助平台的介绍 2556078
邀请新用户注册赠送积分活动 2477241